Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
This research study is looking at biomarkers in DNA samples from patients with acute lymphoblastic leukemia or acute myeloid leukemia. Studying samples of DNA from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

Detailed Description
-----------------
PRIMARY OBJECTIVES: I. Collect DNA samples from patients with cytogenetically, well characterized, and uniformly treated acute lymphoblastic leukemia or acute myeloid leukemia for use in analysis of a wide range of host factors influencing etiology and outcome of the disease. II. Identify host factors that can be determined at onset of treatment to predict outcome of chemotherapy, and thus modify the therapy administered. OUTLINE: Previously collected DNA samples are analyzed for polymorphisms at a variety of loci. Gene expression and expression profiles are correlated with genotype and therapy outcomes.

Official Title
-----------------
Genetic Polymorphisms in ALL Samples Submitted to Gene Array Analysis

Conditions
-----------------
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Promyelocytic Leukemia With PML-RARA, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia, Childhood Acute Myeloid Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia

Intervention / Treatment
-----------------
* Other: Laboratory Biomarker Analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DNA samples available from patients meeting the following criteria: Infants with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) Patients with pre-B ALL, including responders vs non-responders in selected genotypes [hyperdiploid, hypodiploid, t(12;21), t(9;22), t(1;19), and t(4;11)] and responders and non-responders regardless of genotype Pediatric patients with AML registered on POG-9421 Adult patients with ALL, including t(8.21), inv(16), t(15;17), complex cytogenetics, and secondary AML Pediatric patients with relapsed ALL enrolled on COG-AALL01P2 Pediatric patients enrolled on COG-9900 and other CCG or POG trials
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ancillary-Correlative (genetic polymorphisms)<br>Previously collected DNA samples are analyzed for polymorphisms at a variety of loci. Gene expression and expression profiles are correlated with genotype and therapy outcomes. | Other: Laboratory Biomarker Analysis<br>* Correlative studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences in induction outcome, dichotomized into complete remission or no remission | Assessed with Fisher's exact test. | Up to 8 years | 
| Differences in induction outcome, dichotomized into complete remission or no remission | Assessed with Pearson's chi square statistic test | Up to 8 years | 
| Differences in overall survival | Evaluated using the log rank statistic. | Up to 8 years | 
| Disease-free survival (DFS) | Evaluated using the log rank statistic. | Time from the end of induction to relapse or death, assessed up to 8 years | 
| Relapse-free survival | Evaluated using the logrank statistic. | Time from the end of induction to marrow relapse or death from progressive disease, censoring on deaths from other causes, assessed up to 8 years | 
| Etiology of leukemia: Chi square test | Chi square test will be used to determine the differences in distribution of genotypes between cases and controls. | Up to 8 years | 
| Etiology of leukemia: Fisher's exact test | Fisher's exact test will be used to determine the differences in distribution of genotypes between cases and controls. | Up to 8 years |